International Stem Cell Stock

International Stem Cell EBIT

The EBIT of International Stem Cell (ISCO) as of Aug 8, 2026 is -267,000.00 USD. In the previous year, EBIT was -68,000.00 USD — a change of 292.65% (lower).

EBIT

-267,000.00USD

YoY

292.65%

Last updated:

In 2026, International Stem Cell's EBIT was -267,000.00 USD, a 292.65% increase from the -68,000.00 USD EBIT recorded in the previous year.

The International Stem Cell EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (k USD)
Date
EBIT (k USD)
Jan 1, 2022
-196.00 base
Jan 1, 2023
-663.00 base
Jan 1, 2024
-68.00 base
Jan 1, 2025
-267.00 base
Jan 1, 2026 (e)
432.19 base
Jan 1, 2027 (e)
676.94 base
Jan 1, 2028 (e)
584.25 base
Jan 1, 2029 (e)
631.33 base
YEAREBIT (k USD)
2029 est 631.33
2028 est 584.25
2027 est 676.94
2026 est 432.19
2025 -267.00
2024 -68.00
2023 -663.00
2022 -196.00
2021 -1,671.00
2020 -2,818.00
2019 -5,728.00
2018 -3,474.00
2017 -6,010.00
2016 -4,851.00
2015 -4,564.00
2014 -8,558.00
2013 -7,546.00
2012 -
2011 -11,360.00
2010 -10,460.00
2009 -7,200.00
2008 -5,530.00
2007 -6,070.00
2006 -5,720.00
Access this data via the Eulerpool API

International Stem Cell Revenue

International Stem Cell Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
8.18 M USD
-196,000.00 USD
-331,000.00 USD
Jan 1, 2023
7.79 M USD
-663,000.00 USD
-131,000.00 USD
Jan 1, 2024
9.09 M USD
-68,000.00 USD
-209,000.00 USD
Jan 1, 2025
9.10 M USD
-267,000.00 USD
-418,000.00 USD
Jan 1, 2026 (e)
7.32 M USD
432,190.00 USD
-5.76 M USD
Jan 1, 2027 (e)
11.46 M USD
676,936.00 USD
-2.56 M USD
Jan 1, 2028 (e)
9.89 M USD
584,248.00 USD
-4.32 M USD
Jan 1, 2029 (e)
10.69 M USD
631,331.00 USD
-9.29 M USD

International Stem Cell Margins

International Stem Cell stock margins

The International Stem Cell margin analysis displays the gross margin, EBIT margin, as well as the profit margin of International Stem Cell. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for International Stem Cell.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
60.04 %
-2.40 %
-4.05 %
Jan 1, 2023
59.16 %
-8.51 %
-1.68 %
Jan 1, 2024
58.57 %
-0.75 %
-2.30 %
Jan 1, 2025
55.68 %
-2.93 %
-4.59 %
Jan 1, 2026 (e)
55.68 %
5.91 %
-78.77 %
Jan 1, 2027 (e)
55.68 %
5.91 %
-22.35 %
Jan 1, 2028 (e)
55.68 %
5.91 %
-43.70 %
Jan 1, 2029 (e)
55.68 %
5.91 %
-86.88 %

International Stem Cell Stock analysis

What does International Stem Cell do? International Stem Cell Corp (ISCO) is a biotechnology company founded in 2005 and headquartered in Carlsbad, California. It specializes in the development and manufacture of stem cell products for therapeutics and research purposes. ISCO specializes in the production of "human parthenogenetic stem cells" (hpSCs). This means that they produce stem cells from human egg cells that can replicate without fertilization by sperm. The company is a leader in this field and has filed over 80 patents worldwide. ISCO has various business areas, including life science research, therapeutics, dermatology, and animal health. The company partners with various industries, including academic institutions, pharmaceutical and biotechnology companies, and government agencies. One of their biggest partnerships is with the Chinese company Sino Biopharmaceuticals. ISCO offers a variety of products, including in vitro diagnostics for testing genetic diseases such as Huntington's and food allergies. However, the diagnostics division of the company is a small department primarily focused on research and development purposes. ISCO also has a dermatology division called Lifeline Skin Care, which manufactures skincare products based on human stem cells. These products have been developed for improving skin texture and reducing scars. Lifeline Skin Care is a luxury brand for skincare products currently sold in over 15 countries worldwide. In terms of animal health, ISCO recently launched a new division called Lifeline Animal Health. They are developing animal therapeutics based on hpSCs. The company has already developed the first animal therapeutic for dogs approved for the treatment of hip dysplasia. However, ISCO primarily focuses on the development of therapeutics for human stem cells. The company aims to be a global leader in the development of stem cell therapeutics. Their first product, CytoCor for heart disease, is already in clinical phase 1b/2a. The drug is intended to help reduce damage after a heart attack and improve heart function. ISCO also plans to develop therapeutics for other indications, including Alzheimer's disease, based on hpSCs. The company has a strong partnership with the California Institute for Regenerative Medicine, which focuses on stem cell research and their use in medicine. ISCO is a leading company in stem cell research and development. They have a unique approach to stem cell production and offer a variety of products and services for various industries. The company aims to develop groundbreaking stem cell therapeutics and change the way diseases are treated. International Stem Cell is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing International Stem Cell's EBIT

International Stem Cell's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of International Stem Cell's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

International Stem Cell's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in International Stem Cell’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about International Stem Cell stock

EBIT of International Stem Cell is -267,000.00 USD in 2026.

EBIT of International Stem Cell changed from -68,000.00 USD to -267,000.00 USD, representing a 292.65% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT International Stem Cell since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's International Stem Cell historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — International Stem Cell

All Key Metrics — International Stem Cell